ELISA News and Research

RSS

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Researchers identify 87G7, a SARS-CoV-2 neutralizing human monoclonal antibody with remarkable broad-spectrum neutralization and protection efficacy.

21 Feb 2022

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

researchers determine the strong neutralizing mucosal component emanating from intramuscular administration of an mRNA vaccine.

21 Feb 2022

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

Researchers have developed a new vaccine candidate that is specifically targeted against the SARS-CoV-2 Omicron variant.

20 Feb 2022

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Researchers developed a ‘bait and capture’ system which was further followed by a multiplexed and targeted proteomic liquid chromatography-tandem mass spectrometry analyses for the comparison of immune correlates in response to vaccination, natural infection, as well as protection against SARS-CoV-2 variants.

18 Feb 2022

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

Researchers recently assessed SARS-CoV-2-specific humoral and cellular immune responses induced by the second and third doses of the BNT162b2 COVID-19 messenger ribonucleic acid-based vaccine in the elderly.

17 Feb 2022

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

The present study entailed assessments of both infected and uninfected SOTRs against the D614G-CoV2 baseline virus and eight other variants.

17 Feb 2022

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Researchers recently evaluated the efficacy of the Oxford ChAdOx1 (AZD 1222/ AZD2816) vaccine against the Omicron, Delta, and Beta variants of SARS-CoV-2 in Syrian hamsters.

17 Feb 2022

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

A new study explored the high immunogenicity and stability of lyophilized mRNA-LNP vaccines in relation to SARS-CoV-2.

16 Feb 2022

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

In a recent study posted to the medRxiv* preprint server, researchers evaluated the cross-reactivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-triggered neutralization and fragment crystallizable (Fc) effector functions between coronavirus disease 2019 (COVID-19)-vaccinated and unvaccinated individuals in South Africa.

16 Feb 2022

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Researchers study antibodies against various SARS-CoV-2 epitopes that may be responsible for neutralizing activities in recovered COVID-19 patients.

15 Feb 2022

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

In a new study, researchers investigated whether neutralizing antibodies against the SARS-CoV-2 spike protein offered adequate immunity against breakthrough infections among vaccinated individuals.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Researchers suggest that extracellular vimentin may act as a coreceptor to allow for SARS-CoV-2 entry into cells.

14 Feb 2022

Study demonstrates associations between COVID-19 symptom presentation and antibody assay reactivity

Researchers tested convalescent sera from individuals who had recovered from SARS-CoV-2 infection to demonstrate an association between antibody response and reported COVID-19 symptoms.

14 Feb 2022

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.

14 Feb 2022

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

The study highlights the significance of mix-and-match vaccine regimens to diversify the immune responses against highly mutated variants of SARS-CoV-2 such as Omicron.

10 Feb 2022

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Researchers investigated the dynamics and longevity of neutralizing antibody response up to 480 days after the onset of infection in convalescent COVID-19 patients.

9 Feb 2022

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

In a new study, researchers revealed that the nucleotide-binding oligomerization domain-like receptors or NOD-like receptors family pyrin domain containing 3 (NLRP3) inflammasome is activated by the exosomes from plasma in COVID-19.

9 Feb 2022

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

In a recent study published in the journal ACS Applied Bio Materials, researchers demonstrated the inhibitory potential of curcumin-encapsulated polysaccharide nanoparticles (CUR−PS-NPs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (CoV2-SP)-stimulated cytokine storm in lung and liver epithelial cells.

8 Feb 2022

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

In a recent research article published in the journal of Science Immunology, a team of researchers from Japan performed longitudinal analysis on the cellular composition of receptor-binding domain (RBD) memory B cell subsets and its antibody binding and neutralizing activity against the Beta, Delta, and Omicron variants following the second dose of a messenger ribonucleic acid (mRNA) vaccine.

8 Feb 2022

ELISA News and Research

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

COVID-19 vaccine-induced immunity in heart and kidney solid organ transplant recipients

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Study demonstrates associations between COVID-19 symptom presentation and antibody assay reactivity

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News